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1. Introduction 
Cystic fibrosis (CF; OMIM 602421, see OMIM link in the website section) is the most 
common lethal genetic disease of the Caucasian population, with a very variable prevalence, 
from 1/25000 to 1/900, depending on the geographical region (O'Sullivan & Freedman, 
2009; Riordan, 2008). CF is caused by mutations of the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene (Kerem et al.,  1989; Rommens et al.,  1989; Zielenski et 
al.,  1991) (see Ensembl link in the website section), which encodes for a transmembrane 
multifunctional protein expressed mainly in epithelia (Trezise et al.,  1993a; Yoshimura et al.,  
1991b) but also in several cell types of nonepithelial origin (Yoshimura et al.,  1991a). It is an 
ATP- and cAMP-dependent Cl- channel with the main function performed at the apical 
membrane of epithelial cells. This function is the Cl- ion secretion in the colon and airways, 
or its reabsorption in sweat glands (Riordan, 2008; Vankeerberghen et al.,  2002). In the lung, 
the main targeted organ of CF, an additional crucial function performed by CFTR is the 
regulation of the epithelial Na+ channel (ENaC) activity. The exact mechanism of CFTR – 
ENaC interaction is not completely understood and contrasting evidences exist about the 
role of ENaC in CF. The most reliable vision of the basic defect is that, in the airway 
epithelia of CF patients, a CFTR deficiency causes an anomalous dual ion transport 
associated to an altered water absorption (Mall et al., 1998; Stutts et al., 1995; Berdiev et al., 
2009) that, in turn, leads to sticky mucus and impaired mucociliary clearance (Donaldson et 
al.,  2002; Matsui et al.,  1998). The immune response greatly contributes to increased mucus 
viscosity through bacterial lysis and DNA release, as well as through immune cell death in 
the airways. Bacterial infections and inflammation produce bronchial obstruction, 
bronchiectasis, atrophy and, eventually, lung insufficiency. A probably non-exhaustive list 
of other CFTR functions includes:  the bicarbonate secretion (Kim & Steward, 2009); the 
regulation of several other ionic channels and of the ion composition of intracellular 
compartments, as well the control of intracellular vesicle transport (Vankeerberghen et al.,  
2002); antibacterial activity exerted by epithelial cells (Pier et al.,  1997; Schroeder et al.,  
2002) and macrophages (Del Porto et al.,  2011; Di et al.,  2006); maintenance of a correct 
level of hydration, essential for a physiologic development of male reproductive apparatus 
(Dube et al.,  2008; Patrizio & Salameh, 1998; Trezise et al.,  1993a), testis, pancreas, liver and 
intestine (O'Sullivan & Freedman, 2009; Ratjen & Doring, 2003); critical role in 
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spermatogenesis (Trezise et al.,  1993a; Trezise et al.,  1993b; Xu et al.,  2011b), sperm 
fertilizing capacity (Xu et al.,  2007) and inflammatory response (Belcher & Vij, 2010; 
Buchanan et al.,  2009; Campodonico et al.,  2008; Mattoscio et al.,  2010). The phenotypic 
severity of CF is essentially referable to CFTR residual function (Estivill, 1996; Zhang et al.,  
2009) that in turn depends on a combination of variables acting on the CFTR gene, transcript 
and/or protein, as well as to the action of variables external to CFTR. Random variability 
and the effect of the environment also influence the final phenotype (Figure 1). Depending 
on this complex situation, clinical manifestations of CF are highly variable. Some mono- or 
oligo-symptomatic phenotypes, namely the CFTR-related disorders (CFTR-RD), should 
have to be distinguished from poly-symptomatic classic CF (Dequeker et al.,  2009). Nearly 
all male CF patients and several CFTR-RD male subjects show obstructive azoospermia due 
to congenital bilateral absence of the vas deferens (CBAVD); over 80% of CF patients show 
pancreatic insufficiency.  The clinical history of CF patients is characterized by progressive, 
age-dependent, multiresistant bacterial infections of the lung, where the main pathogens are 
Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae, and the Burkholderia 
cepacia complex. Lung colonization causes the clinical decline, characterized by respiratory 
impairment, that is the main cause of morbidity and mortality. Despite advances in the 
treatment of CF, there is no definitive cure, the survival median of CF patients being at 
present limited to approximately 40 years . 
2. The genetics of cystic fibrosis 
The CFTR gene is located on the long arm of chromosome 7 (7q31.2), spans about 250 kb and 
contains 27 exons (Zielenski et al.,  1991). The most common transcript is 6128 bases long 
and it is translated to a protein of 1480 aminoacids. The CFTR is under control of an 
housekeeping-type promoter with a time- and tissue-specific regulated expression 
established by alternative transcription start sites and/or alternative splicing 
(Vankeerberghen et al.,  2002). CF is a monogenic autosomal recessive disease. Affected 
subjects have both the alleles mutated. When the same mutation is present on both alleles 
they are called homozygotes, whereas when different mutations are present on the 2 alleles 
they are called compound heterozygotes. A carrier of only 1 mutation on 1 allele has no 
clinical symptoms but has a genetic risk. Two carriers have a high risk of 1/4 (25%) of 
having an affected child and a risk of 1/2 (50%) of having a healthy carrier child, with a 
residual probability of 1/4 (25%) of having a healthy non-carrier child. In a given 
population, the frequency of couples at high risk depends on the frequency of carrier 
individuals. The prevalence of CFTR mutations and carrier frequency, as well as the 
incidence of CF, are highly variable depending on geographical region and ethnic group. 
The disease is very common among Europeans and white Americans with an incidence of 
about 1/3000 (about 1/27 carriers), whereas the incidence is lower in African Americans 
(1/17000) and Asian Americans (1/30000). It is uncommon in Africa and Asia with, for 
example, an incidence as low as 1/350000 in Japan. A comprehensive analysis of worldwide 
CF incidence and ethnic variations is available (Bobadilla et al.,  2002; O'Sullivan & 
Freedman, 2009).  
The basic view of the CF genetics explained above is complicated by biological variability, 
gene network and technical limitations in the mutational search. A more complex view is 
reported below. 
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2.1 Maturation, protein domains and mutational classes 
The CFTR gene codes for a symmetric transmembrane protein of 1480 aminoacids that 
belongs to the family of ATP-binding cassette transporters (ABC transporters). The CFTR 
protein undergoes a complex transport and maturation process within the cell (Rogan et al.,  
2011; Vankeerberghen et al.,  2002). Through an initial co-translational transport, the 
polypeptide is included in the membranes of the endoplasmic reticulum (130 kDa form) and 
is N-glycosylated (150 kDa form). By interacting with chaperones the polypeptide assumes 
the correct folding with a relatively low efficiency of about 25%, the remainder being 
degraded by the proteasome. Then it is transported to Golgi apparatus where, after further 
glycosylation, it becomes the mature CFTR (170 kDa form). It is then transported to the cell 
membrane where it performs its multiple functions, with a half-life of about 12 to 24 h. The 
CFTR protein exists in a cAMP-regulated dynamic condition of endocytosis and recycling in 
clathrin-coated vesicles. Finally it is degraded within lysosomes. After this complex 
pathway to intracellular and plasma membranes and owing to its multiple functions, the 
CFTR protein contains a number of different domains, each functionally specialized (Rogan 
et al.,  2011; Vankeerberghen et al.,  2002). Its NH2-end interacts with the SNARE-proteins 
Syntaxin 1A (STX1A) and synaptosome-associated protein of 23 kDa (SNAP23) (Peters et al.,  
2001; Tang et al.,  2011). The first (TMD1) and the second (TMD2) transmembrane domains, 
both consisting of six transmembrane helices, form the physical pore through the 
membrane. The nucleotide binding domains 1 (NBD1) and 2 (NBD2), functionally 
interacting, contain the sites for ATP binding and hydrolysis. The ATP binding to NBD1 site 
initiates channel activity, whereas the ATP binding to NBD2 site allows the formation of the 
intramolecular NBD1 – NBD2 tight heterodimer that turns the channel in a stable open state; 
the hydrolysis of the ATP bound at NBD2 starts the disruption of the heterodimer interface 
and finally leads to channel closure (Gadsby et al., 2006). The regulatory domain (R) 
contains most of the PKA, PKC and PKG phosphorylation sites and has a regulatory role in 
channel opening/closing. The ATP binding is allowed only after channel activation by PKA-
dependent phosphorylation of the R domain. It also interacts with the SNARE protein 
Syntaxin 8 (STX8) (Bilan et al.,  2004). The COOH-end interacts with PDZ domains of the 
CFTR-associated protein 70 (CAP70) (Wang et al.,  2000a), of the Na+/H+ exchanger 
regulatory factor (NHERF, which in turn interacts with ezrin) (Seidler et al.,  2009) and of 
the CFTR associated ligand (CAL) (Cheng et al.,  2002). It also interacts with the 1 AMP-
activated protein kinase (AMPK) (Hallows et al.,  2000) and contains an internalization 
signal (Prince et al.,  1999) and a binding site for the AP-2 adaptor complex (Weixel & 
Bradbury, 2000), needed for correct endocytosis. 
CFTR mutations are at the present grouped into 6 classes (Table 1), according to their effects 
on transcription, cellular processing, final localization and quantitative level of functional 
protein (Amaral & Kunzelmann, 2007; O'Sullivan & Freedman, 2009; Rogan et al.,  2011; 
Vankeerberghen et al.,  2002). Class I identifies mutations with a complete lack of protein 
production. Usually they are nonsense mutations, severe splicing mutations (which produce 
only aberrant mRNA), small or large deletions or insertions. They act by generating in-
frame or frameshift premature stop codons. The unstable transcripts and/or proteins 
formed are rapidly degraded or retain no functionality. In the class II are grouped protein 
trafficking defects based on ubiquitination and increased degradation, within the 
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endoplasmic reticulum, of the misfolded protein. These are processing/maturation defects 
that severely decrease the protein quantity in the apical membrane, although often in a 
tissue-specific manner. In class III are included mutations leading to defective regulation 
that impair channel opening. Although the CFTR protein is able to reach the apical 
membrane, it is not properly activated by ATP or cAMP. The effect is a decrease or absence 
of functional CFTR protein. In class IV are grouped the defects of reduced Cl- transport 
through CFTR. In this case the CFTR is present at the apical membrane but it is unable to 
properly sustain the Cl- flux. Most of mutations included in classes II, III or IV are missense 
ones, that produce different degrees of CFTR impairment in reaching the cell apical 
membrane or in functioning although correctly localized. In some cases, however, also small 
deletions or insertions can be found. Class V mutations are splicing defects that cause a 
reduction of wild-type CFTR mRNA. At variance from the splicing mutations belonging to 
class I, the splicing mutations grouped in this class V do not completely abolish the correctly 
spliced form. Mutations of class VI decrease the stability of CFTR or affect the regulation of 
other channels. They can be missense mutations but also nonsense mutations possibly 
generating overdue stop codons, that allow the production of a protein that retains a partial 
Cl- transport ability but is unable to correctly regulate other proteins. 
2.2 The significance of genetics for personalized therapies 
The increased knowledge about CFTR derived from over 20 years of basic and applied 
researches. This allowed both the development of symptom-based treatments, already in use, 
that greatly enhanced the life quality and lifespan of patients and the actual possibility of more 
effective personalized therapies. As well, a promise of primary defect correction also arose. As 
the most severe clinical aspect is respiratory impairment, the target tissue of these therapies is 
the pseudostratified epithelia of airways. A normalization of ion and water transport in 
respiratory epithelium can be achieved with the correction of less than 25% of the airway 
epithelial cells (Farmen et al.,  2005; Johnson et al.,  1992; Zhang et al.,  2009). To classify a CFTR 
mutation in a functional class has recently become meaningful for a restoring strategy based on 
drugs acting on specific functional impairment (the so-called mutation-specific therapy) 
(Amaral & Kunzelmann, 2007; Becq et al.,  2011; Kerem, 2005; Rogan et al.,  2011) (Table 1). 
Particularly studied are the in-frame premature termination codons (class I). In general, many 
kind of tumours and more than a third of genetic diseases are originated by premature 
termination codons (Frischmeyer & Dietz, 1999). Also in CF, about 20% of affected subjects have 
at least 1 mutation that is an in-frame premature termination codon. Aminoglycoside antibiotics 
have shown to be useful to suppress in-frame premature termination codons by read-through 
and production of full-length CFTR protein (although a wrong aminoacid is inserted in each 
individual protein) allowing the targeting of class I mutations. The rationale of this approach is 
that a population of CFTR proteins each with a different wrong aminoacid will show an overall 
functionality greater than a population of identically truncated CFTR proteins. In this regard, 
recent findings, although not specifically obtained for CF, highlighted a surprisingly therapeutic 
potentiality for ribonucleoproteins. The authors (Karijolich & Yu, 2011) demonstrated the 
possibility, in vitro and in yeast, of the conversion of uridine into pseudouridine, a chemical 
transformation known as pseudouridylation. As all three translation termination codons 
contain a uridine residue at first position and the pseudouridylated nonsense codons code for 
serine, threonine tyrosine or phenylalanine, this may be a tool for converting nonsense into 
sense codons. Also in this case a wrong aminoacid will be inserted, although within a reduced 
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choice of 4 aminoacids. Notably, the ribonucleoprotein complex used by the authors contain a 
RNA guide able to target the complex to a specific nonsense mutation. Chemical, molecular or 
pharmacological chaperones, usually called correctors (of trafficking), have been reported to be 
useful, by promoting protein folding and stabilizing CFTR structure, in the targeting of class II 
mutations. By increasing the activation of mutated CFTR correctly localized at the apical 
membrane and/or by extending its half-life, some drugs act as potentiators (of function) and are 
suitable for the targeting of class III, IV and V mutations. Class VI mutations may be targeted by 
either potentiators or suppressors of in-frame termination codons. Extensive lists of promising 
compound are available (Amaral & Kunzelmann, 2007; Becq et al.,  2011; Rogan et al.,  2011). 
For an up-to-date  description of CF clinical trials see, in the website section, the links to the U.S. 
National Institutes of Health Clinical trials registry and database, and to the U.S. CF Foundation 
drug development pipeline.  
The topic of mutational classes and personalized therapy is not devoid of problems. Some 
mutations produce multiple effects and should be classified in multiple classes. An emblematic 
example is the CFTR worldwide most common mutation, the F508del, a deletion of 
phenylalanine at position 508 of the CFTR protein. It is a class II mutation, because most of the 
protein is degraded within the endoplasmic reticulum; a small proportion of it reaches however 
the apical membrane where it behaves as a class III mutation, with only a limited capacity to 
bind ATP. In addition, the F508del protein has shown a decreased stability and an enhanced 
degradation also in post-endoplasmic reticulum compartments (Sharma et al.,  2001), a 
behaviour that would point to the mutational class VI. It is in general quite difficult to classify a 
mutation without specific experimental studies aimed to its functional characterization. Due to 
the complexity of such studies, they have been performed only for a very limited number of the 
over 1800 sequence variations found in the CFTR gene. On the other hand, only in a limited 
number of cases it is possible to infer, by a theoretical approach, a relationship between the 
functional impairment and the protein domain where the mutation is located, as well a 
relationship between a specific DNA sequence variation and the class it should belong to. For 
example, although most of class III mutations localize in the R, NBD1 or NDB2 domains and 
most of class IV mutations localize in TMD1 or TMD2, if a missense mutation in these domains 
has been found, it cannot be assumed that the effect will effectively correspond to class III or IV, 
since that mutation might have a prevalent effect on protein trafficking and should therefore be 
classified as class II. Likewise, only for nonsense and frameshift mutations it is possible to 
reasonably assume a direct classification in class I, while for all other kinds of mutations it is 
very difficult to recognize the mutational class just from DNA sequence variation. For example, 
for splicing mutations it can be hazardous to deduce the possible amount of anomalous splicing 
only by software analysis, since just a limited amount of wild type mRNA would cause the shift 
of that mutation from class I to class V.  Taking into account these considerations, although the 
class-specific personalized therapeutic approach can be at the moment applied only to a limited 
amount of CFTR mutations, its enhancement is foreseeable when the gap between the 
knowledge of the structure and the effect of a mutation will be filled by increasing numbers of 
mutation-specific functional studies.  
Gene therapy would be the resolutive therapeutic intervention. Although, since the 
discovery of CFTR gene in 1989 more than 30 clinical trials of gene therapy have been 
undertaken, no gene therapy has been so far approved for clinical use (Conese et al.,  2011; 
Davies & Alton, 2011; Griesenbach & Alton, 2011). The problems arose from the repeated 
administration of adenovirus- and adeno-associated virus-based vectors shifted the 
approaches to lentiviral vectors and non-viral strategies, as well as cell therapy. The 
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evidence that a lot of work is still to be done in laboratory to optimize gene therapy tools 
arose. Two opposite approaches can be distinguished in gene therapy: the gene 
augmentation and the gene targeting. By the former approach, the entire wild-type CFTR 
gene, producing a normal gene function, is introduced into the cell without the need to 
know the specific CFTR mutation. On the contrary, the latter approach is a mutation-specific 
gene therapy strategy, as only the zone of mutation is targeted in situ, allowing the 
correction of the mutated zone of the gene. A recent study (Auriche et al.,  2010) of gene 
augmentation in CF used the entire CFTR locus, including regulatory regions, cloned and 
delivered by a bacterial artificial chromosome (BAC), a non-viral vector. The possibility to 
obtain a physiologically regulated CFTR expression and activity, also of Pseudomonas 
internalization, in an in vitro cellular system has been demonstrated. The control of CFTR 
activity by naturally occurring regulatory elements appeared a critical aspect to obtain a 
physiologic CFTR expression pattern, to be taken under consideration in the planning of 
gene augmentation strategies. By the gene targeting, the corrected gene remains regulated 
by its endogenous regulatory machinery maintaining its physiologic expression pattern. 
Recent researches (Gruenert et al.,  2003; Sangiuolo et al.,  2008; Sangiuolo et al.,  2002) 
applied to CF an intriguing gene targeting strategy, the Small Fragment Homologous 
Replacement (SFHR), that exchange a wild-type corrector DNA fragment with the 
endogenous mutated sequence, through a still undefined mechanism probably based on 
homologous recombination. Both approaches have to be enhanced before clinical 
application. The main difficulties encountered in the BAC approach are efficient 
manipulation and delivering to the proper cell population. The main hitches with SFHR are 
the low reproducibility and recombination efficiency, ranging from 0.01% to 5% (Gruenert et 
al.,  2003). In both cases additional studies are needed to clarify the respective driving 




Functional effect Kind of mutations Mutation-specific therapy 
I 
Complete lack of protein 
production 
Premature stop codons by: 
- nonsense 
- severe splicing 
- small or large deletions or 
insertions 














Defective regulation of 
channel opening 
- missense 
- small deletions or insertions 
Potentiators 
IV Reduced Cl- transport 
- missense 
- small deletions or insertions 
Potentiators 
V 
Reduction of wild-type 
mRNA 
- partial splicing Potentiators 
VI 
Protein decreased stability 
or impaired ability of 
other channel regulation 
- missense 
- nonsense (overdue stop 
codons) 
Potentiators or 
suppressors of in-frame 
overdue termination 
codons 
Table 1. Classes of CFTR mutations and possible personalized therapeutic interventions. 
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2.3 The complexity and sources of variability in the genotype – Phenotype 
relationship of the CF and CFTR-RD 
Separation of classic CF from CFTR-RD only represents a starting attempt to organize the 
great clinical variability of CF (Bombieri et al.,  2011; Dequeker et al.,  2009; Estivill, 1996; 
Noone & Knowles, 2001). In fact, within classic CF are usually grouped both poly-
symptomatic and oligo-symptomatic forms greatly differing in the involvement of lung, 
pancreas, liver, sweat gland and reproductive apparatus (to consider only the main CF 
targets). Not easier is the task of categorizing the even more heterogeneous oligo- and 
mono-symptomatic CFTR-RD. In this regard CFTR mutations have been linked to a wide 
series of pathologies: obstructive azoospermia for CBAVD (Claustres, 2005; Cuppens & 
Cassiman, 2004; Stuhrmann & Dork, 2000); non-obstructive azoospermia, reduced sperm 
quality and spermatogenesis defects (Boucher et al.,  1999; Dohle et al.,  2002; Jakubiczka et 
al.,  1999; Jarvi et al.,  1998; Mak et al.,  2000; Pallares-Ruiz et al.,  1999; van der Ven et al.,  
1996); male hypofertility due to idiopathic seminal hyperviscosity (Elia et al.,  2009; Rossi et 
al.,  2004); female hypofertility due to thick cervical mucus (Gervais et al.,  1996; Hayslip et 
al.,  1997); neonatal hypertrypsinaemia with normal sweat test (Castellani et al.,  2001a; 
Gomez Lira et al.,  2000; Narzi et al.,  2007; Padoan et al.,  2002); idiopathic pancreatitis 
(Castellani et al.,  2001b; Gomez Lira et al.,  2000; Maire et al.,  2003; Pallares-Ruiz et al.,  
2000); pulmonary diseases (Bombieri et al.,  1998; Bombieri et al.,  2000); disseminated 
bronchiectasis (Girodon et al.,  1997; Pignatti et al.,  1995); chronic rhinosinusitis (Raman et 
al.,  2002; Southern, 2007; Wang et al.,  2000b); nasal polyposis (Kerem, 2006; Pawankar, 
2003); metabolic alkalosis, hypochloremia, hyponatriemia, hypokalemia and dehydration 
(Augusto et al.,  2008; Kerem, 2006; Leoni et al.,  1995; Priou-Guesdon et al.,  2010; Salvatore 
et al.,  2004); primary sclerosing cholangitis, biliary cirrhosis and portal hypertension 
(Collardeau-Frachon et al.,  2007; Gallegos-Orozco et al.,  2005; Girodon et al.,  2002; Kerem, 
2006; Sheth et al.,  2003). Several CFTR-RD are still debated, as the involvement of CFTR 
mutations is often inferred from small case series or even isolated case reports, as well for 
controversial results (as for example for non-CBAVD male reproductive defects). In 
addition, in several cases only one mutated allele could be found by quite non homogeneous 
methodological approaches of mutational search. This raises the troublesome question 
whether it should be assumed that 2 mutated alleles are indeed present, but the mutational 
search protocol applied was unable to identify both of them, or if the possibility of CFTR-RD 
arising in heterozygotes might also be taken into consideration. Rather than an approach for 
categories, a vision of a mosaic of different clinical manifestations combined in a peculiar 
way in each patient, overall constituting a continuous gradient of disease clinical severity, 
seems to better reflect the reality.  
Only a rough correspondence between mutational classes and clinical outcome can be found 
with, for example, more severe phenotypes generated by the combination of class I and class 
III mutations and milder phenotypes originated by class IV and V. The variability is 
however so high that clinicians usually do not use genotypes for prognosis. The problem of 
the relationship between genotype and phenotype in CF can be partitioned in, at least, 2 
steps (Figure 1). The first step concerns the production of a CFTR protein with reduced 
functionality starting from a mutated CFTR genotype. The second step concerns the clinical 
manifestations that originate owing to the protein malfunction. It is generally accepted that 
the clinical severity of CF and CFTR-RD is correlated with the residual function of CFTR 
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(Estivill, 1996; Zhang et al.,  2009). It is easy to collocate high (almost physiological) levels of 
CFTR protein at the same end of the spectrum of the strictly mono-symptomatic patients 
and very low (almost absent) levels to the other end, where the poly-symptomatic patients 
with severe clinical manifestations are ideally collocated. Within these extreme conditions, it 
is however very difficult to link the values of CFTR residual activity to the severity of 
clinical manifestations. This not only because of the lack of systematic studies, but also for 
the difficulty of measuring in a real quantitative manner both the CFTR residual function 
and the clinical severity. Although CFTR mutated genotypes responsible for intermediate 
levels of residual activity often consist of a classic mutation on one allele and a mild 
mutation, retaining some CFTR activity, on the other allele, also the link between a specific 
mutated genotype and its effect on the protein functionality is elusive. Again, also in this 
case, the lack of systematic functional studies, addressing in vitro the effect of the mutated 
genotype on the protein cellular fate, have greatly hampered the knowledge at this level.    
Several sources of variability influence both steps and make the overall picture unclear 
(Figure 1).  
 
Fig. 1. The variability determinants of the genotype – phenotype relationship in CF and 
CFTR-RD.  
The first step (from mutated genotype to residual function) is mainly influenced by 
structural and functional intragenic (CFTR-depending) variability. The structural intragenic 
variability is due to the large number of mutations  and to the even larger number of their 
combinations both in trans, to originate homozygous and compound heterozygous 
genotypes, and in cis, with more than one mutation on the same allele to form the complex 
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alleles. Trans and cis variability may also combine leading, for instance, to genotypes with 2 
complex alleles and 4 different mutations each belonging to a different mutational class. The 
functional intragenic variability is due on one side to the variable impairment effect of 
mutations and, on the other side, to the influence of both post-transcriptional and post-
translational modifications, possibly with overlapping effects and interacting mechanisms. 
The second step (from residual function to clinical phenotype) is more likely to be 
influenced by extragenic variability due to genes different from CFTR. Modifier genes can 
indeed modulate the original effect of CFTR mutations (Collaco & Cutting, 2008; Cutting, 
2010; Merlo & Boyle, 2003; Salvatore et al.,  2002; Slieker et al.,  2005), as evidenced by the 
high phenotypic variability found in some subjects with identical CFTR mutated genotypes.  
Reciprocal influence between modifier genes and interactome (Wang et al.,  2006), as well as 
an effect of interactome on intragenic functional variability, might also influence this step. 
Furthermore, it should be taken under consideration that the CFTR levels physiologically 
required can be tissue-specific, with only some organs affected despite the same CFTR 
residual function (Estivill, 1996). For example, the male reproductive apparatus appears as 
the most sensitive district to CFTR impairment, as nearly all men with CF (lower levels of 
functional CFTR) exhibit also CBAVD while, on the contrary, men with only CBAVD 
(higher level of functional CFTR) do not have other organs targeted. Superimposed to these 
genetic sources of variability the powerful role of environmental and random factors on 
both steps should not be undervalued. Due to these sources of variability, the genotype - 
phenotype relationship in CF is still poorly understood (Salvatore et al.,  2011) with, 
therefore, our diagnostic, prognostic and therapeutic abilities severely limited. 
3. Complex alleles and modifier genes 
3.1 The relevance of complex alleles 
The least addressed aspect of CFTR intragenic structural variability probably is the 
involvement of complex alleles, with two (or more) mutations in cis (on the same allele). 
Unfortunately, the most widely used protocols for a mutational search within the CFTR 
gene are designed only with the aim of finding the first two mutations on different alleles; 
additional mutations, possibly in cis with the already found mutations, may escape 
detection. The result is that the mutated genotypes of CF subjects with varying clinical 
presentations may appear identical, despite the presence of unfound complex alleles that 
might explain the divergent phenotypes. Undetected complex alleles may have important 
consequences. For example, if 2 already known disease-causing mutations have been found 
on both alleles (also on the allele with an in cis undetected additional mutation), the 
consequences will be an unclear genotype – phenotype relationship with prognostic failure. 
If at least 1 sequence variation with unclear functional significance in cis with an undetected 
additional disease-causing mutation has been found, a diagnostic error and/or  
misclassification of the sequence variation will arise. A systematic experimental search for 
complex alleles has not yet been undertaken. Probably for this reason only few complex 
alleles have been found so far and their prevalence is unknown. A probably non exhaustive 
list of CFTR complex alleles at the moment known is reported in Table 2. They have been 
more frequently found in patients with CF than CFTR-RD. Only in some cases an in vitro 
functional characterization has been performed, with the consequence that only in a limited 
number of these alleles it is possible to distinguish the relative functional contribution of 
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Complex allele Bibliographic source
[R75Q;S549N] Consortium for CF genetic analysis database  
[(TG)mT5;2184insA] Consortium for CF genetic analysis database  
[129G>C;R117H] Consortium for CF genetic analysis database  
[F508del;R553Q] (Dork et al.,  1991);(Teem et al.,  1993) 
[3732delA;K1200E] Consortium for CF genetic analysis database  
[F508C;S1251N] (Kalin et al.,  1992)
[F508del;R553M] (Teem et al.,  1993)
[R117H;(TG)mTn] 
(Kiesewetter et al.,  1993; Massie et al.,  2001; 
Peckham et al.,  2006) 
[125G>C;R75X] Consortium for CF genetic analysis database  
[R297Q;(TG)mTn] Consortium for CF genetic analysis database  
[R668C;3849+10kbC>T] Consortium for CF genetic analysis database  
[deleD7S8 (CFTR 3’ 500 kb); F508del] (Wagner et al.,  1994)
[1716G>A;L619S] Consortium for CF genetic analysis database  
[405+1G>A;3030G>A] Consortium for CF genetic analysis database  
[G576A;R668C] (McGinniss et al.,  2005; Pignatti et al.,  1995) 
[(TG)mT5 ;A800G] (Chillon et al.,  1995)
[L88X;G1069R] (Savov et al.,  1995)
[S912L;G1244V] (Clain et al.,  2005; Savov et al.,  1995) 
[R334W;R1158X] (Duarte et al.,  1996)
[R347H;D979A] (Clain et al.,  2001; Hojo et al.,  1998) 
[-102T;S549R(T>G)] (Romey et al.,  1999)
[R74W;D1270N] (Fanen et al.,  1999)
[G628R;S1235R] (Mercier et al.,  1995; Wei et al.,  2000) 
[R117C;(TG)mTn] (Massie et al.,  2001)
[M470V;S1235R] (Wei et al.,  2000)
[I148T;3199del6] (Rohlfs et al.,  2002)
[S1235R;(TG)mT5] (Feldmann et al.,  2003)
[L24F;296+2T>G] Consortium for CF genetic analysis database  
[W356_A357del;V358I] (McGinniss et al.,  2005)
[V562I;A1006E] (McGinniss et al.,  2005)
[R352W;P750L] (McGinniss et al.,  2005)
[1198_1203delTGGGCT;1204G>A] (McGinniss et al.,  2005)
[V754M;CFTRdele3_10,14b_16] (Niel et al.,  2006)
[F508del;I1027T] (Fichou et al.,  2008)
[R74W;R1070W;D1270N] (de Prada et al.,  2010)
[(TG)11T5 ;A1006E] (Tomaiuolo et al.,  2010)
[R117L;L997F] (Lucarelli et al.,  2010)
Nucleotide notation: A = adenine, C = cytosine, G = guanine, T = thymine. 
Aminoacid notation: A = alanine, C = cysteine, D = aspartic acid, E = glutamic acid, I = isoleucine, K = 
lysine, E = glutamic acid, , F = phenylalanine, G = glycine, L = leucine, M = methionine, N = asparagine,  
H = histidine, P = proline, Q = glutamine, R = arginine, S = serine, T = threonine, V = valine, W = 
tryptophan, X = stop codon (nonsense). 
The link to the Consortium for CF genetic analysis database is reported in the website section. 
Table 2. Complex alleles of CFTR (in chronological order of discovery). 
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each mutation. They often result in a combination of two mild mutations that, if isolated, cause 
CFTR-RD but if combined in cis originate CF. In some cases there is one main mutation whose 
phenotypic effect is worsened by a second sequence variation that may even be a neutral 
variant if isolated, such as F508C , R74W , S912L or M470V. Also variants that have a 
suppressive effect when in cis but originate a hyperactive CFTR when combined in trans, as 
for example the M470 and R1235, have been described. On the other hand, the finding of 
complex alleles also in CFTR-RD suggests the possibility that an additional mutation in cis 
may even lead to a lessening of the phenotypic severity  (Mercier et al.,  1995). This effect has 
been demonstrated for -102T, R553Q, R553M and R334W. The situation is further complicated 
by the fact that some CFTR polymorphisms, combined in specific haplotypes, may have at 
least CFTR-RD as phenotypic consequences (Steiner et al.,  2004; Steiner et al.,  2011).    
3.2 The relevance of modifier genes 
A small fraction of CF patients and a higher amount of CFTR-RD subjects remain with no 
CFTR mutations, also when high sensitivity methods of mutational search are used. In 
addition, CF and CFTR-RD patients with the same mutated CFTR genotypes often show 
divergent phenotypes. Also some intriguing cases have been reported: an unaffected sister 
who inherited the same CFTR alleles, without mutations, of her CF brother (Mekus et al.,  
1998) and two CF sibs, with no CFTR mutation found, who had inherited different parental 
CFTR allele (Groman et al.,  2002). This suggested that genes different from CFTR may cause 
CF or CFTR-RD. The involvement of other genes in the definition of these phenotypes is 
relevant for the comprehension of both the molecular pathogenesis and the genotype – 
phenotype relationship. However, the widest action of the modifier genes probably is to 
modulate the CF final clinical phenotype in patients with both CFTR mutations found. Even 
more important, the modifier genes can represent excellent therapeutic targets, as they are 
able, by definition, to modify the clinical outcome of the disease but they are not mutated 
(on the contrary to the CFTR). A so-called bypassing approach has been proposed to correct 
the CF ionic imbalance by stimulating alternative ionic pathways that might compensate the 
impaired CFTR (Amaral & Kunzelmann, 2007). At present a comprehensive list of these 
genes does not exist and little is known about their effects and molecular mechanisms of 
action, as well as about their exact kind of interaction, if any, with the CFTR. Several 
putative modifier genes have been reported (Collaco & Cutting, 2008; Cutting, 2010; Merlo 
& Boyle, 2003; Slieker et al.,  2005) to influence the second step, from CFTR residual 
functionality to clinical outcome. On the other hand, microRNA, known to exert a post-
transcriptional regulation, have recently been shown to potentially influence the CFTR 
protein levels (Gillen et al.,  2011; Xu et al.,  2011a). Together with complex alleles, it is these 
genes that most probably represent the greatest source of variability in CF. Furthermore, 
modifier genes show tissue-specific levels of activity, that combine with equally tissue-
specific CFTR levels, thus amplifying the complexity of the network. They may also 
influence the different CFTR functions, even in a tissue-specific manner. One of the most 
interesting gene complex proposed as CF modifier is the epithelial Na+ channel (ENaC).   
3.2.1 The ENaC genes 
The human functional ENaC is composed of 3 subunits coded by 3 genes with sequence 
similarities: (SCNN1A gene) (Voilley et al.,  1994),  (SCNN1B gene) and  (SCNN1G gene) 
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(Voilley et al.,  1995). The ENaC protein has the functional properties of a Na+ channel with 
high Na+ selectivity, low conductance and amiloride sensitivity. It is expressed in human 
epithelial cells that line the distal renal tubule, distal colon and several exocrine glands; an 
ENaC-mediated amiloride-sensitive electrogenic Na+ reabsorbtion has been documented in 
the upper and lower airways (Hummler et al.,  1996). Genetic diseases are caused by either 
loss- or gain-of-function mutations in the ENaC genes: loss-of-function mutations in one of the 
three subunits cause pseudohypoaldosteronism type I (PHA-I) (Chang et al.,  1996) 
characterized by severe renal dysfunction, arterial hypotension and reduced reabsorbtive 
capacity of both kidney and lung; gain-of-function mutations in either SCNN1B or SCNN1G 
are responsible for Liddle’s syndrome, a severe form of hypertension (Shimkets et al.,  1994). 
Interestingly, some PHA-I patients, without CFTR mutations, also exhibit CF-like lung 
symptoms, such as recurrent bacterial infection of the airways (Hanukoglu et al.,  1994). 
Because of the involvement of both CFTR and ENaC in the physiologic dual ion transport,  it 
was supposed that also ENaC deregulation and/or molecular lesions might sustain CF or 
CFTR-RD. There are indeed experimental evidences validating this hypothesis. The over-
expressing -ENaC mouse model has CF-like pulmonary symptoms, with morbidity and 
mortality partially reduced by preventive treatment with amiloride, an inhibitor of the ENaC 
channel (Zhou et al.,  2008). Wild type CFTR has been shown, in a heterologous cellular system 
and in polarized primary human bronchial epithelial cultures, to prevent the proteolitic 
stimulation of ENaC, thus downregulating Na+ absorption (Gentzsch et al.,  2010). Enhanced 
expression of all the 3 ENaC genes was shown in the nasal epithelium of CF patients (Bangel et 
al.,  2008). In human bronchial epithelial cells, the CFTR regulates the functional surface 
expression of endogenous ENaC, by influencing its trafficking (Butterworth, 2010; Rubenstein 
et al.,  2011). However, also experimental evidences against a direct involvement of ENaC 
and/or of CFTR - ENaC interaction in CF pathogenesis have been provided. According to one 
study (Joo et al., 2006), CF airway submucosal glands do not display ENaC-mediated fluid 
hyperabsorption, differently from the ciliated cells of the airway surface. Another study (Nagel 
et al., 2005) evidenced that human CFTR fails to inhibit the human ENaC channel in a 
heterologous experimental system of Xenopus oocytes. Finally, no increased sodium 
absorption has been found in newborn CFTR-/- pigs, an animal model with features 
resembling those of human CF disease (Chen et al., 2010). The differences between CF and 
CFTR action in humans and pigs, the fact that the study has been conducted only shortly after 
birth and that CF patients have a mutated CFTR and not a  CFTR-/-, should however be taken 
into account. Following the above considerations, mutational search in the ENaC genes have 
been performed in CF and CFTR-RD patients. Both, loss-of-function (Huber et al.,  2010; 
Sheridan et al.,  2005) and gain-of-function (Mutesa et al.,  2008; Sheridan et al.,  2005) 
mutations have been found in the SCNN1B gene of CFTR-RD patients. Several variants of 
SCNN1B and SCNN1G have been also found in bronchiectasis patients, some of them with 
only one CFTR mutation. A significantly increased prevalence of ENaC rare polymorphisms 
have been found in CFTR-RD patients (Azad et al.,  2009), with some of these variants 
producing  alterations of ENaC activity (Azad et al.,  2009; Huber et al.,  2010).  The bulk of 
these data allows to ascribe to ENaC some roles in CF and/or CFTR-RD. This is reinforced also 
by the findings of physical and functional co-regulatory interactions between SNARE proteins 
(in particular Syntaxin 1A) and both the CFTR and ENaC (Peters et al.,  2001). It is likely that 
wild-type ENaC is deregulated by the mutated CFTR. Moreover, ENaC genes can also act as 
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additional mutated genes either when only one or no copy of CFTR is mutated (the ENaC 
genes behaving as concomitant pathogenetic factors with respect to CFTR) or when both 
copies of the CFTR gene are mutated (the ENaC genes as modifiers, modulating the CF 
phenotype). Little is known about the prevalence and kind of mutations, as well as about the 
role of other kind of ENaC alterations, such as transcriptional modifications. This last point is 
quite intriguing considering that a deregulation of ENaC, rather than mutations of it, seems 
more frequently the main pathogenic mechanism. The topic of the regulation of ENaC activity 
further increases the complexity of the puzzle, as multiple biochemical and cellular pathways 
are involved in the lung (Bhalla & Hallows, 2008; Butterworth, 2010; Eaton et al.,  2010; 
Edinger et al.,  2006; Gaillard et al.,  2010; Gentzsch et al.,  2010). However, little is known 
about the tissue-specific expression of ENaC and the coordinated transcriptional regulation of 
the 3 SCNN1 genes. The structure of these genes suggested a role for DNA methylation. The 
SCNN1G gene has 2 CpG islands in its promoter region and exon 1 (Auerbach et al.,  2000; 
Zhang et al.,  2004), the SCNN1B gene has 1 CpG island in its promoter and exon 1 (Thomas et 
al.,  2002) and the SCNN1A gene has a high density of CpG sites, that are however not 
organized in a CpG island (Ludwig et al.,  1998). In effect, experimental evidences suggest that 
DNA methylation can control transcription of the SCNN1G gene (Zhang et al.,  2004).  
In general, the search for new genes involved in genetic diseases, in addition to the 
identification and characterization of new pathogenetic mechanisms, allows the 
identification of new therapeutic targets. The functional interaction between CFTR and 
ENaC evidenced by the vast majority of experimental data makes ENaC genes attractive 
therapeutic targets, since it looks easier to attempt the correction of the regulation of wild 
type ENaC than the correction of the mutated CFTR. The ENaC gene activity repression has 
been tempted by amiloride, with partially contrasting results obtained in humans (Burrows 
et al.,  2006)  and animal models (Zhou et al.,  2008). Also RNA interference seems a valuable 
and specific tool (Caci et al.,  2009; Yueksekdag et al.,  2010). The experimental evidences 
that ENaC genes undergo a DNA methylation-dependent transcription, raised new 
therapeutic opportunity in epigenetics and chromatin remodelling. 
4. The genetics, biochemistry and clinics in the diagnosis of CF 
Due to the wide range of signs and symptoms, CF and CFTR-RD diagnosis is difficult, 
particularly in infancy. On the other hand, CF early diagnosis, revealing pancreas 
insufficiency, preventing malnutrition and allowing a prompt treatment of lung infections, 
improves both lifespan and quality of life. In addition, it allows the early selection of high 
risk couples. For these reasons, neonatal screening programs have been activated worldwide 
(Castellani & Massie, 2010; Lai et al.,  2005; Southern et al.,  2007). The most used neonatal 
screening procedure is based on a single or double dosages (at birth and later on, between 
the third and fifth week of life) of immunoreactive trypsinogen (IRT), possibly combined 
with a I level mutational analysis (Castellani et al.,  2009; Narzi et al.,  2002). In addition to 
CF newborns, it has been demonstrated that also CFTR-RD newborns are selected by the 
screening programs  (Boyne et al.,  2000; Castellani et al.,  2001a; Massie et al.,  2000; Narzi et 
al.,  2007; Padoan et al.,  2002). In a part of newborns positive to the neonatal screening, only 
one or even no CFTR mutation, sometimes linked to borderline sweat test values, are found. 
This raises diagnostic uncertainty (Parad & Comeau, 2005) and provides evidence that some 
carriers are selected by neonatal screening (Castellani et al.,  2005; Laroche & Travert, 1991; 
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Scotet et al.,  2001).  A common effect of the introduction of CF neonatal screening is the 
progressively increasing number of CF diagnoses performed each year by screening and the 
decreasing number of diagnoses performed by symptoms. By definition, neonatal screening 
selects a lot of false positive subjects and, consequently, is not a diagnostic procedure. On 
the other hand, also several other pathologies different from CF have a positive sweat test, 
as well as some CF and a lot of CFTR-RD subjects have a borderline or even negative sweat 
test. In some cases measurements of the nasal potential difference and/or intestinal Cl- flux 
appear to be quite useful procedures. Taking into account also the highly variable clinical 
manifestations of CF and CFTR-RD, some of which superimposable to those of other 
pathologies, it became clear that none of this measurements alone allows a full diagnosis of 
CF or CFTR-RD. For these reasons, as stated by recent general (Farrell et al.,  2008), neonatal 
screening-oriented (Castellani et al.,  2009; Mayell et al.,  2009; Sermet-Gaudelus et al.,  2010), 
sweat test-oriented (Green & Kirk, 2007; Legrys et al.,  2007) and genetic-oriented (Castellani 
et al.,  2008; Dequeker et al.,  2009) guidelines, the diagnosis of CF and CFTR-RD may only 
be made by a coordinated evaluation of clinical, biochemical and genetic data (Figure 2 
upper part). In the last years genetic assessment has been clearly emerging as the most 
crucial point. In fact if 2 CF or CFTR-RD disease-causing mutations on the different alleles 
are found, a reliable diagnosis can be defined. Both the finding of the CFTR mutations and 
their functional interpretation are however very critical points, as described below.      
4.1 The technical complexity of the mutational search in the CFTR gene 
Over 1500 CFTR mutations and 300 polymorphisms are at moment known (in the website 
section see the links to the Consortium for CF genetic analysis database and to the human gene 
mutation database (HGMD)). The F508del is the worldwide most common mutation, 
accounting, on average, for about 60% of mutated alleles in northern European and North 
American populations. Few other single mutations account for more than about 5%. In addition 
the frequencies of CFTR mutations are very different depending on the geographical area 
(Bobadilla et al.,  2002; O'Sullivan & Freedman, 2009). The simplest approach of mutational 
search would be to define a panel of mutations to be included in a rapid and low-cost test 
allowing a direct search. However, the high genetic heterogeneity has at least 2 consequences 
that limit such an approach. First, it is impossible to establish a general mutational panel 
applicable worldwide; second, the allelic detection rate, also of geographical optimized 
mutational panels, rarely exceeds the 80% and often is quite lower (Bobadilla et al.,  2002; 
O'Sullivan & Freedman, 2009; Tomaiuolo et al.,  2003). The detection rate is the genetic 
equivalent of the laboratory operative characteristics called diagnostic sensitivity. In this case it 
represents the proportion of mutated alleles that the specific genetic test is able to evidence. The 
practical consequence of a limited detection rate is that in case of a negative test, the presence of 
a mutation not included in the analyzed panel of mutations can not be excluded. A widely 
accepted approach of mutational search is the multistep one. Usually, methods of I, II and III 
levels are recognized (Figure 2 lower part). The I level methods are based on the search panels 
of the most common CFTR mutations by entry-level techniques. They are the most commonly 
used methods worldwide. However, due to technical and cost limitations, they show a low 
detection rate as at best they search for the most common CFTR mutations of the specific 
geographical area. At the moment commercial methods able to search near all CFTR mutations 
of specific geographic areas are not available. The I level genetic tests are therefore of limited 
prognostic and diagnostic usefulness, particularly in CFTR-RD subjects with borderline clinical 
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and/or biochemical values. In this case, the use of methods with higher detection rate  are 
fundamental to resolve uncertain diagnoses.  The II level methods are scanning procedures 
usually able to analyze all the exons, adjacent intronic zones and proximal 5’-flanking of the 
CFTR gene. In last years, several enhanced methods specific for CFTR scanning have been 
developed as for example denaturing gradient gel electrophoresis (Costes et al.,  1993; Fanen et 
al.,  1992), single-strand conformation polymorphism and heteroduplex analysis (Ravnik-
Glavac et al.,  1994), denaturing high pressure liquid chromatography (D'Apice et al.,  2004; Le 
Marechal et al.,  2001; Ravnik-Glavac et al.,  2002), and re-sequencing (Lucarelli et al.,  2002; 
Lucarelli et al.,  2006). Due to the progressively reducing costs of the re-sequencing and to the 
need of further characterization by re-sequencing of positive findings of other scanning 
techniques, the re-sequencing has become the most used II level method. However, no 
mutational scan technique able to detect all the CFTR mutations exists. Also the re-sequencing, 
at the moment the method of mutational search with the highest detection rate, is able to select 
about 97% of CFTR mutations. The remaining 3% of alleles carry mutations not identified. 
These may be large deletions, completely intronic mutations that may reveal cryptic exons and 
mutations in the distal 5’-flanking as well as 3’-UTR zones. Although little is known about the 
geographical variability of the prevalence of this kind of mutations, due to their overall limited 
amount and to the extended analysis of the CFTR gene, the re-sequencing shows not only a 
higher, but also a more constant detection rate than mutational panel-based techniques. 
Automated protocol of re-sequencing, as well as software templates for automated analysis of 
re-sequencing data  (Ferraguti et al.,  2011), have also greatly reduced the time and efforts 
needed for both the experimental and data processing phases.  It should be clear that the use of 
scanning techniques may raise the problem of functional interpretation of sequence variations 
found. In fact, whereas the mutational panels are usually planned as to include only disease-
causing CFTR mutations, by using scanning procedures also sequence variations not previously 
characterized from functional point of view may be selected. This may complicate the genetic 
counselling. The III level methods should be aimed to the search for large deletions, full intronic 
and distal 5’-flanking, as well as 3’-UTR, mutations. In practise, commercially available 
products only exist either for the search of most common CFTR large deletions or for the CFTR 
scanning for gene dosage (gain or loss of genetic material). Although full intronic, distal 5’-
flanking and 3’-UTR mutations are assessable by re-sequencing, only recently some efforts have 
been done to value the pathogenetic contribution of these kind of mutations to CF and CFTR-
RD.  Whatever technique based on PCR and/or hybridization is applied, the possibility that 
polymorphisms within the primer/probe recognition sequence may interfere with the pairing 
reactions should be taken under consideration. So, also if the detection rate is kept to a 
maximum by including all the 3 levels of mutational search, a full assessment of mutations is 
virtually impossible to reach, due to the likely, even if small, decrease in analytical sensitivity.   
The practical application of this multistep approach changes depending on its use in 
subjects with disease suspect for diagnostic purposes or in general population subjects for 
genetic risk lowering. In  the first case it is reasonable to progressively go through the levels 
up to the finding of 2 CFTR mutations on different alleles. If no mutation is found (or at least 
1 mutation is not found) even at the III level, the genetic test contributes to a reasonable 
exclusion of the CF or CFTR-RD diagnosis. On the contrary, in the second case, since it can 
be difficult to apply all mutational search levels to each subject checking its carrier status, an 
appropriate genetic residual risk is usually chosen and the mutational search with the 
suitable detection rate is performed.  
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Fig. 2. The genetic analysis, biochemical assessment and clinical presentation contribute to 
the diagnosis of CF. The multistep genetic approach allows a progressive increase of 
detection rate and diagnostic value of the test in subjects with CF or CFTR-RD suspect, as 
well as a progressive decrease of carrier risk in general population subjects.  
Usually, no scanning techniques are applied for genetic risk lowering , also because of the 
possibility to select sequence variations hardly valuable from a pathogenetic point of view. 
The use of the I level mutational panel approach to assess the genetic risk raises 4 
possibilities. If both members of the couple are positive to the mutational search, the risk for 
an affected child is 1/4 (25%). If both members of the couple are negative the residual risk is 
so low that no other action is required, although it should be kept in mind that the risk is not 
zero and this should be made clear to the couple by the genetic counselling. For example, 
with a carrier frequency of 1/27 and a detection rate of the applied mutational panel of 
about 85%, the couple residual risk of having an affected child, with CFTR mutations 
different from those analyzed, if the genetic tests are both negative is about 1/120000. An 
intermediate residual risk arises when one member of the couple is carrier or CF. In these 
cases, considering the same above carrier frequency and detection rate, the risk is, 
respectively, of about  1/700 and 1/350. In these cases, in addition to the genetic counselling 
clarifying that a concrete risk exists, a possible extension of mutational search to further 
lower the genetic risk may be taken under consideration for the negative partner.    
Following the above considerations, the often incomplete genetic characterization of CF and 
CFTR-RD patients is due to technical limitations; this constitute a further obstacle to our 
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understanding of the genotype – phenotype relationship. An emblematic example of this are 
undetected complex alleles. Patients who do not undergo full mutational assessment, have 
discordant sweat test and/or clinical outcome, but show at a first mutational search 
apparently identical CFTR mutated genotypes, should undergo the search for complex alleles. 
The rising, within the last years, of parallel sequencing, also called next generation sequencing 
(NGS) (Su et al.,  2011), allows to identify a possible IV level in the CFTR mutational search 
(Bell et al.,  2011) (Figure 2 lower part). The possibility to study and analyze data of the whole 
genomic CFTR sequence (including introns, distal 5’-flanking and 3’-UTR zones) by massive 
re-sequencing, in an almost complete automated single run-based manner, will be a real 
possibility within next years. The NGS also has the potentiality to simultaneously study the 
genetics of modifier genes and, in general, of CFTR interactome to obtain a full assessment of 
genetic variability determining the final phenotype. If this kind of approach will be able to 
completely replace the multistep approach actually used is only matter of costs, investment 
and, finally, commercial choices. Several websites deal with CF and CFTR genetics, from 
diagnostic and quality assessment point of view, for example those of the European CF 
thematic network and of the European CF society (links reported in website section).  
5. Conclusion 
The comprehension of the gene network involved in CF and CFTR-RD is increasing. This is 
coupled with the enhancement of mutational search methodologies that allow the search for 
a continuously increasing number of mutations and sequence variations in the CFTR gene 
and in several other CF-related genes. The huge amount of structural data has to be 
supported by proper functional studies of single mutations, sequence variations, complex 
alleles and haplotypes. Only this will produce a full comprehension of genes and their 
molecular lesions cooperating in the definition of the final CF and CFTR-RD phenotypes, 
allowing full diagnosis and prognosis. As well, this will also allow the actual clinical use of 
mutation-specific therapies. When, in the mid-term, this objectives will be reached, the 
effect-oriented therapy now used will be turned into a cause-oriented therapy (Figure 3).  
 
Fig. 3. A genetic-oriented view of CF and CFTR-RD therapy perspectives. The increasing 
knowledge about genetics, genomics and functional genomics change the therapy.  
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